Page results
-
Our Getting Ready for Transition (GReaT) to secondary school parent information session will run on Wednesday 28 January 2026.
-
Your treatment for acute lymphoblastic leukaemia (ALL) will be delivered within a number of comprehensive specialised services led by medical and nursing cancer care experts.
-
A multiple sclerosis (MS) patient in the UK is the first to receive CAR T cell therapy in a UCLH clinical trial testing whether this personalised treatment may slow or even halt the progression of the disease.
-
A new service to provide comprehensive care and support for patients living with Sickle Cell disorder is now available in the comfort of their homes thanks to a partnership between UCLH and Whittington Health NHS Trusts.
-
Specialist teams at UCLH and UCL are at the forefront of research which could bring hope to people who have been robbed of their sense of smell and taste after suffering the long-term legacy of COVID-19.
-
The hospital marked the start of the year a visit by HM The Queen in February 2020. A few weeks after this celebration, the pandemic took hold and the hospital stepped up to help.
-
As World Lung Cancer Day approaches (1 August) the SUMMIT Study reports that it has made great strides in catching up with patients whose nodule follow ups were cancelled due to COVID-19.
-
A new toolkit to support babies, children and young people in healthcare access high quality health play services was launched at UCLH last week with UCLH chief nurse Vanessa Sweeney welcoming visitors from NHS England and the play charity Starlight.
-
To enable us to provide a quick response when you need it most, we have developed these Frequently Asked Questions (FAQs). We kindly ask you to read through these before contacting our team as you may find the answer to your question here.
-
UCLH is contributing to a national priority trial of the drug ruxolitinib in patients with Covid-19 pneumonia (infection of the lungs).
File results
-
FOI/2022/0557 - Patients treated with Visudyne (verteporfin)
-
FOI/2022/0563 - Ambulatory cardiac monitoring
-
FOI/2022/0544 - Wards/ departments that provide services to 0-17 year-olds
-
FOI/2022/0545 - Criteria used in determining acceptance of GP referrals for osteoporosis treatment, and for priorisation of osteoporosis appointments
-
FOI/2022/0546 - Metastatic Cholangiocarcinoma (CCA) or Acute myeloid leukaemia
-
FOI/2022/0548 - Biologic and biosimilar products within Rheumatology
-
FOI/2022/0549 - SACT (systemic anti-cancer therapy) /cervical cancer treatments
-
FOI/2022/0550 - Patients that have been treated for glioblastoma brain cancer
-
FOI/2022/0553 - Patients tested for non-small cell lung cancer biomarkers
-
FOI/2022/0561 - Regulation (EU) 2016/425 Declarations of Conformity for all type IIR surgical masks provided as PPE to staff